Monthly Archives: March 2015

Hyperion Therapeutics Receives a Hold from Brean Capital

Brean Capital analyst Difei Yang reiterated a Hold rating on Hyperion Therapeutics (NASDAQ: HPTX) yesterday. The company’s shares opened today at $45.90, close to its 52-week high of $46.96. Yang noted, “Horizon Pharma plc (HZNP , Buy) is to acquire

Canaccord Genuity Reiterates a Buy Rating on Acuity Brands

In a report released yesterday, Jonathan Dorsheimer from Canaccord Genuity reiterated a Buy rating on Acuity Brands (NYSE: AYI), with a price target of $187. The company’s shares opened today at $168.16, close to its 52-week high of $172.76. Dorsheimer

MLV & Co. Reiterates a Buy Rating on Argos Therapeutics

In a report released today, Arlinda Lee from MLV & Co. reiterated a Buy rating on Argos Therapeutics (NASDAQ: ARGS), with a price target of $13. The company’s shares opened today at $8.91. Lee commented, “Yesterday, ARGS reported 4Q14 EPS

Compass Point Believes ALEX Won’t Stop Here

Compass Point analyst Wilkes Graham reiterated a Buy rating on Alexander & Baldwin (NYSE: ALEX) today and set a price target of $62. The company’s shares opened today at $42.85, close to its 52-week high of $43.08. Alexander & Baldwin

Compass Point Believes TWOU Won’t Stop Here

Compass Point analyst Michael Tarkan reiterated a Buy rating on 2U (NASDAQ: TWOU) today and set a price target of $29. The company’s shares opened today at $23.81, close to its 52-week high of $24.07. 2U has an analyst consensus

Barclays Believes FBHS Won’t Stop Here

Barclays analyst Stephen Kim reiterated a Buy rating on Fortune Brands (NYSE: FBHS) today and set a price target of $51. The company’s shares opened today at $46.92, close to its 52-week high of $48.02. Fortune Brands has an analyst